S-1: Genprex Secures $12.5 Million Equity Commitment from Lincoln Park Capital Amidst Ongoing Clinical Trials and Nasdaq Compliance Efforts

Genprex, a clinical-stage gene therapy company, has entered into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $12.5 million in common stock, while advancing its oncology and diabetes programs and addressing Nasdaq listing requirements.

Summary

• Genprex, Inc. has filed an S-1 Registration Statement for the resale of up to 15,000,000 shares of its common stock by Lincoln Park Capital Fund, LLC.
• This includes 1,186,859 'Commitment Shares' already issued to Lincoln Park for its commitment, and up to 13,813,141 'Purchase Shares' reserved for future issuance.
• Under the Purchase Agreement, Genprex may sell up to an aggregate of $12.5 million of common stock to Lincoln Park over a 24-month period, with the purchase price based on market prices at the time of sale.
• The company will not receive any cash proceeds from the initial issuance of the Commitment Shares, but may receive up to $12.5 million from future sales to Lincoln Park.
• As of June 10, 2025, the closing price of Genprex's common stock was $0.32 per share, implying that selling the full 13,813,141 registered shares would yield approximately $4.42 million, significantly less than the $12.5 million commitment, suggesting further share registration would be needed to reach the full amount.
• The company has a history of operating losses and its independent auditor expressed substantial doubt about its ability to continue as a going concern as of December 31, 2024.
• Genprex recently regained compliance with Nasdaq's minimum stockholders' equity requirement, reporting $3,867,855 as of March 31, 2025, but remains non-compliant with the $1.00 minimum bid price requirement, with a deadline of August 6, 2025.
• In its oncology pipeline, the company is enrolling patients in the Phase 2a expansion of the Acclaim-1 trial (REQORSA + Tagrisso for NSCLC) and the Phase 2 expansion of the Acclaim-3 trial (REQORSA + Tecentriq for ES-SCLC).
• The Acclaim-2 trial (REQORSA + Keytruda for NSCLC) ceased enrollment in August 2024 due to challenges and delays.
• For its diabetes gene therapy program (GPX-002), preclinical studies are ongoing, and the company expects to seek further FDA guidance on IND-enabling studies in the second half of 2025.
• Genprex formed a wholly-owned subsidiary, Convergen Biotech, Inc., on February 18, 2025, to focus on the diabetes clinical development program.

Sentiment

Score: 4

Explanation: While the company has made progress in clinical trials and regained Nasdaq equity compliance, the persistent 'going concern' doubt from auditors, the ongoing Nasdaq minimum bid price issue, and the highly dilutive nature of the Lincoln Park financing agreement indicate significant financial challenges and risks for investors. The cessation of one clinical trial also adds a negative note.

Positives

• Genprex successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, reporting $3,867,855 in stockholders' equity as of March 31, 2025.
• The Acclaim-1 (NSCLC) and Acclaim-3 (ES-SCLC) clinical trials are actively enrolling and treating patients in their respective Phase 2a/2 expansion portions.
• REQORSA, the lead oncology drug candidate, has received FDA Fast Track Designation for both Acclaim-1 and Acclaim-3, and Acclaim-3 also holds FDA Orphan Drug Designation.
• One patient in the Phase 1 portion of the Acclaim-1 study achieved a partial remission and has maintained this response for approximately 36 months, continuing treatment.
• Preclinical data for the diabetes gene therapy (GPX-002) in a non-human primate model showed statistically significant improvements, including decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance.
• The company secured a new sponsored research agreement with the University of Pittsburgh in May 2025 to continue studies on Type 1 and Type 2 diabetes in animal models, incorporating recent technologies.

Negatives

• The company has a history of operating losses since inception and expects to incur additional near-term losses.
• The independent registered public accounting firm expressed substantial doubt about Genprex's ability to continue as a going concern in its audit report for the fiscal year ended December 31, 2024.
• Genprex is not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share and has until August 6, 2025, to regain compliance, with a reverse stock split being a potential consideration.
• The Acclaim-2 trial was ceased in August 2024 due to enrollment challenges, delays, and resource prioritization, indicating difficulties in patient recruitment for certain studies.
• The Purchase Agreement with Lincoln Park Capital, while providing capital access, will result in substantial dilution to existing stockholders, with up to 15,000,000 shares being registered for resale.
• The potential gross proceeds from the currently registered shares under the Lincoln Park agreement are significantly less than the total $12.5 million commitment, implying further dilutive share issuances may be necessary to fully utilize the facility.

Risks

• The sale of common stock to Lincoln Park may cause substantial dilution to existing stockholders and the subsequent resale of these shares could cause the stock price to fall.
• The company may not have access to the full $12.5 million available under the Purchase Agreement due to market conditions, Nasdaq listing rules (Exchange Cap), or Lincoln Park's beneficial ownership limitations.
• Genprex requires additional financing to sustain operations and fund development, and there is no assurance that such financing will be available on favorable terms or at all, which could lead to the inability to continue operations.
• The company's management will have broad discretion over the use of proceeds from the Lincoln Park agreement, and these proceeds may not be used effectively to improve financial condition or market value.
• There is inherent uncertainty in developing marketable products, obtaining regulatory approvals, and successfully commercializing gene therapies.
• The company's ability to maintain compliance with Nasdaq's continued listing requirements, particularly the minimum bid price, is uncertain and could lead to delisting.
• Clinical trials are subject to risks including delays, enrollment challenges, and potential failures, as evidenced by the cessation of the Acclaim-2 trial.
• The company is dependent on third-party suppliers and manufacturers for its products and raw materials, and their failure to supply or manufacture adequately could disrupt development programs.
• Maintaining and protecting intellectual property rights is crucial, and involvement in litigation could be expensive and divert management's attention.
• Changes in government regulation affecting product candidates or third-party reimbursement policies could adversely impact development costs and future sales.

Future Outlook

Genprex plans to continue advancing its clinical trials for REQORSA in NSCLC (Acclaim-1) and ES-SCLC (Acclaim-3), with interim analyses expected in the first half of 2026 for Acclaim-1 and enrollment completion for interim analysis in Q1 2026 for Acclaim-3. For its diabetes gene therapy program (GPX-002), the company intends to conduct additional nonclinical studies and initiate research in Type 2 diabetes animal models, with the goal of seeking further FDA guidance on IND-enabling studies in the second half of 2025. The company also anticipates needing to raise substantial additional capital to fund its operations and execute its business strategy, potentially through the Lincoln Park Purchase Agreement, and will continue to monitor its Nasdaq bid price compliance, considering a reverse stock split if necessary.

Management Comments

• "Our strategy is to develop REQORSA in combination with currently approved therapies and we believe REQORSAs unique attributes position it to provide treatments that improve on these current therapies for patients with NSCLC, SCLC, and possibly other cancers."
• "Although the Acclaim-2 study in patients progressing on Keytruda containing regimens has been closed due to, among other factors, slow enrollment, we continue to believe that this combination could be beneficial."
• "We will continue to monitor the closing bid price of our common stock and assess potential actions to regain compliance with the Minimum Bid Price Requirement and may, if appropriate, consider and effectuate available options, including implementation of a reverse stock split of our common stock."

Industry Context

Genprex operates as a clinical-stage gene therapy company, a highly innovative and rapidly evolving segment of the biotechnology and pharmaceutical industry. Its focus on systemic, non-viral delivery systems (ONCOPREX) for tumor suppressor genes in oncology and adeno-associated virus vectors for diabetes gene therapy positions it within cutting-edge therapeutic areas. The company's collaborations with prominent academic institutions like The University of Texas MD Anderson Cancer Center and the University of Pittsburgh are common strategies for early-stage biotech firms to leverage research expertise and accelerate development. The challenges faced, such as clinical trial enrollment difficulties and the need for continuous capital raises, are typical for clinical-stage companies in this capital-intensive sector, especially given the long development timelines and high regulatory hurdles for gene therapies.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant potential dilution of economic and voting interests due to the issuance and resale of up to 15,000,000 shares of common stock under the Lincoln Park Purchase Agreement.
• Shareholders: Risk of decline in share price due to future sales by Lincoln Park or the anticipation of such sales, and potential delisting from Nasdaq if the minimum bid price requirement is not met.
• Company Operations: The capital raised from Lincoln Park is intended for working capital and general corporate purposes, including R&D and clinical trials, which could support continued operations and development, but the going concern opinion indicates ongoing financial challenges.
• Patients: Continued development of REQORSA for NSCLC and SCLC, and GPX-002 for diabetes, offers potential future treatment options, although the cessation of Acclaim-2 highlights clinical development risks.

Next Steps

• Continue enrolling and treating patients in the Phase 2a expansion portion of the Acclaim-1 clinical trial.
• Complete enrollment of the first 19 patients for interim analysis in the Phase 2a Acclaim-1 study by the first quarter of 2026, with interim analysis expected in the first half of 2026.
• Continue enrolling and treating patients in the Phase 2 expansion portion of the Acclaim-3 clinical trial.
• Complete enrollment of the first 25 patients for interim analysis in the Phase 2 Acclaim-3 study in the first quarter of 2026.
• Perform a Phase 2 futility analysis for Acclaim-3 after the 25th patient enrolled and treated reaches 18 weeks of follow up.
• Continue with planned additional nonclinical studies for the diabetes program (GPX-002), including species analyses for animal models and initiation of research in Type 2 diabetes animal models.
• Seek further regulatory guidance from the FDA on IND-enabling studies for the diabetes program in the second half of 2025.
• Monitor the closing bid price of common stock and assess potential actions, including implementation of a reverse stock split, to regain Nasdaq compliance by August 6, 2025.
• Potentially sell additional shares of common stock to Lincoln Park under the Purchase Agreement to raise up to $12.5 million, subject to market conditions and regulatory caps.
• File one or more additional registration statements with the SEC if more than the currently registered 13,813,141 shares need to be sold to Lincoln Park to receive aggregate gross proceeds equal to the $12.5 million total commitment.

Key Dates

Recommendation

Keywords

Genprex, GNPX, gene therapy, oncology, diabetes, NSCLC, SCLC, REQORSA, GPX-002, clinical trials, SEC filing, S-1, equity financing, Lincoln Park Capital, dilution, Nasdaq compliance, going concern, biotechnology, cancer treatment, diabetes treatment, MD Anderson, University of Pittsburgh, Fast Track Designation, Orphan Drug Designation, Convergen Biotech